dr. burtness on promise of frontline pembrolizumab in metastatic hnscc
Published 5 years ago • 177 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
1:40
dr. burtness on the use of biomarkers in metastatic hnscc
-
1:34
dr. burtness on frontline immunotherapy in head and neck cancer
-
1:23
dr. burtness on the benefit of pembrolizumab in head and neck cancer
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
1:55
dr. burtness on findings of keynote-048 in head and neck cancer
-
5:34
pembrolizumab for recurrent hnscc
-
1:05
dr. burtness on combinations of immunotherapy in head and neck cancer
-
5:24
keynote048: first line pembrolizumab for r/m hnscc
-
1:57
dr. burtness on the future of immunotherapy in head and neck cancer
-
1:43
dr. burtness on ongoing trials of immunotherapy in head and neck cancer
-
0:42
dr. zsiros discusses pembrolizumab triplet in recurrent ovarian cancer
-
1:58
dr. vokes on nivolumab, pembrolizumab approvals in head and neck cancer
-
11:47
pembrolizumab in hnscc
-
1:00
dr. burtness on immunotherapy and radioresistance in head and neck cancer
-
4:42
pembrolizumab for recurrent head and neck squamous cell carcinomas (hnscc)
-
7:06
immunotherapy for hnscc
-
5:22
new therapies for hnscc
-
5:01
patient selection for pembrolizumab in hnscc